Genentech, Inc. Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Apr 10 Calls Today's Calls

Call Details Genentech, Inc. Earnings Conference Call (Q1 2008) Thu, Apr 10, 2008, 4:45 pm Eastern Listen to the archived event audio About Genentech, Inc. (NYSE:DNA) Genentech, Inc. engages in the discovery, development, manufacture, and commercialization of pharmaceutical products in the United States. It markets Avastin (bevacizumab) for the treatment of metastatic cancer of the colon or rectum and metastatic non-squamous non-small cell lung cancer; Rituxan (rituximab) to treat B-cell non-Hodgkin’s lymphoma; Herceptin (trastuzumab) for treating node-positive or node-negative breast cancer; and Lucentis (ranibizumab) for treating neovascular (wet) age-related macular degeneration. The company also commercializes Xolair (omalizumab) for adults and adolescents with asthma; Tarceva (erlotinib) for the treatment of metastatic non-small cell lung cancer, as well as in combination with gemcitabine chemotherapy for the first-line treatment of metastatic pancreatic cancer; and Nutropin and Nutropin AQ growth hormone products for the treatment of growth hormone deficiency in children and adults, growth failure associated with chronic renal insufficiency prior to kidney transplantation, short stature associated with turner syndrome, and long-term treatment of idiopathic short stature. In addition, it offers Activase for the treatment of acute myocardial infarction (heart attack), acute ischemic stroke (blood clots in the brain), and acute massive pulmonary embolism (blood clots in the lungs); TNKase (tenecteplase) to treat heart attack; Cathflo Activase for the restoration of function to central venous access devices in adult and pediatric patients; Pulmozyme for the treatment of cystic fibrosis; and Raptiva (efalizumab) to treat chronic moderate-to-severe plaque psoriasis in adults. The company sells its products to wholesalers, specialty distributors, or directly to hospital pharmacies. It has collaborations with Roche Holding AG; Biogen Idec, Inc.; Novartis Pharma AG; Seattle Genetics, Inc.; Inotek Pharmaceuticals; and OSI Pharmaceuticals, Inc. The company was founded in 1975 and is headquartered in South San Francisco, California. More Info: Quote | Chart | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings